文献速递消化系统肿瘤

曲氟尿苷/替吡嘧啶联合奥沙利铂治疗转移性结直肠癌的I期剂量递增研究

Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.
PubMed 文献 · Eur J Cancer · 2019-03-16

这项I期剂量递增研究在既往至少一线治疗进展的转移性结直肠癌患者中,采用3+3设计探索曲氟尿苷/替吡嘧啶联合奥沙利铂的最大耐受剂量、II期推荐剂量和药代动力学特征,共入组24例。最高剂量组出现1例3级发热性中性粒细胞减少这一剂量限制性毒性,该剂量被确定为最大耐受剂量及推荐剂量;大多数药物相关不良事件为1-2级,推荐剂量下1例部分缓解、7例疾病稳定。

要点

  • 推荐剂量为曲氟尿苷/替吡嘧啶35 mg/m2每日两次、第1-5天、每14天重复,联合奥沙利铂85 mg/m2第1天、每14天重复。
  • 最高剂量组出现1例3级发热性中性粒细胞减少这一剂量限制性毒性,该剂量被确定为最大耐受剂量及推荐剂量。
  • 推荐剂量组(n=14)中1例部分缓解(7.1%)、7例疾病稳定(50.0%)。

核心结论

  • 曲氟尿苷/替吡嘧啶联合奥沙利铂在转移性结直肠癌患者中安全性可控并具有一定疗效,推荐剂量为曲氟尿苷/替吡嘧啶35 mg/m2每日两次、第1-5天、每14天重复,联合奥沙利铂85 mg/m2第1天、每14天重复。

研究设计与样本

  • I期剂量递增研究,采用3+3设计,纳入既往至少一线治疗进展的转移性结直肠癌患者,共24例。
  • 曲氟尿苷/替吡嘧啶剂量从25 mg/m2递增至30、35 mg/m2每日两次、第1-5天、每14天重复,联合固定剂量奥沙利铂85 mg/m2第1天、每14天重复。
  • 另设一个奥沙利铂减量至65 mg/m2的中间队列;确定最大耐受剂量后,继续入组患者以确定II期推荐剂量。

主要发现

  • 最高剂量组出现1例3级发热性中性粒细胞减少这一剂量限制性毒性,该剂量被确定为最大耐受剂量,随后确定为推荐剂量。
  • 最常见的药物相关不良事件为乏力、恶心、腹泻、周围神经病变、中性粒细胞减少、食欲下降、血小板减少、呕吐、贫血和周围感觉神经病变,其中93.0%为1-2级。
  • 奥沙利铂合用未影响曲氟尿苷/替吡嘧啶的药代动力学参数。
  • 推荐剂量组(n=14)最佳总体疗效为1例部分缓解(7.1%)和7例疾病稳定(50.0%)。

关键数值与推荐

  • 推荐剂量:曲氟尿苷/替吡嘧啶35 mg/m2每日两次、第1-5天、每14天重复,联合奥沙利铂85 mg/m2第1天、每14天重复。
  • 最大耐受剂量为曲氟尿苷/替吡嘧啶35 mg/m2每日两次、第1-5天、每14天重复联合奥沙利铂85 mg/m2第1天、每14天重复。
  • 推荐剂量组(n=14)部分缓解率7.1%、疾病稳定率50.0%。
  • 药物相关不良事件中93.0%为1-2级。

临床怎么用

  • 原文结论为该联合方案在转移性结直肠癌患者中安全性可控并具有一定疗效,推荐剂量为曲氟尿苷/替吡嘧啶35 mg/m2每日两次、第1-5天、每14天重复联合奥沙利铂85 mg/m2第1天、每14天重复。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Pre-clinical data have shown that combining trifluridine/tipiracil with oxaliplatin enhances anti-tumour activity compared with either monotherapy. A phase I dose-escalation study was conducted to determine the maximum tolerated dose (MTD), recommended dose (RD) for phase II and pharmacokinetic profile of this combination in patients with metastatic colorectal cancer (mCRC) who had progressed after at least 1 prior line of treatment. METHODS: Using a 3 + 3 design, patients received escalating trifluridine/tipiracil doses from 25, then 30 and to 35 mg/m2 twice daily, days 1-5, q14 days, together with a fixed dose of 85 mg/m2 of oxaliplatin day 1, q14 days. An intermediate cohort with a lower oxaliplatin dose (65 mg/m2) was also investigated. After MTD determination, additional patients were treated to define the RD. RESULTS: Twenty-four patients were enrolled. One dose-limiting toxicity of grade 3 febrile neutropenia was observed at the highest dose level, which was established as the MTD and subsequently the RD. The most common drug-related adverse events (AEs) were asthenia, nausea, diarrhoea, peripheral neuropathy, neutropenia, decreased appetite, thrombocytopenia, vomiting, anaemia and peripheral sensory neuropathy. Most drug-related AEs (93.0%) were of grade 1-2. Pharmacokinetic parameters of trifluridine/tipiracil were not influenced by oxaliplatin co-administration. Best overall responses at the RD (n = 14) included 1 patient with partial response (7.1%) and 7 patients with stable disease (50.0%). CONCLUSION: The combination of trifluridine/tipiracil and oxaliplatin in patients with mCRC has a manageable safety profile with some efficacy. The RD is 35 mg/m2 of trifluridine/tipiracil twice daily, days 1-5, q14 days and 85 mg/m2 of oxaliplatin day 1, q14 CLINICALTRIALS. GOV NUMBER: NCT02848443.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Argilés G, André T, Hollebecque A, et al. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer. Eur J Cancer. 2019. PMID: 30889492. doi:10.1016/j.ejca.2019.01.101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。